Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 23784914)

1.

Arterial hypertension and cancer.

Milan A, Puglisi E, Ferrari L, Bruno G, Losano I, Veglio F.

Int J Cancer. 2014 May 15;134(10):2269-77. doi: 10.1002/ijc.28334. Epub 2013 Jul 31. Review.

PMID:
23784914
2.

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS.

Cancer. 2015 Jan 15;121(2):311-9. doi: 10.1002/cncr.28972. Epub 2014 Sep 18.

PMID:
25236375
3.

Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.

Ferroni P, Della-Morte D, Palmirotta R, Rundek T, Guadagni F, Roselli M.

Curr Vasc Pharmacol. 2012 Jul;10(4):479-93. Review.

PMID:
22272903
4.

Hypertension management in the era of targeted therapies for cancer.

Kurtin SE.

Oncology (Williston Park). 2009 Apr;23(4 Suppl Nurse Ed):41-5. No abstract available.

PMID:
19856597
5.

[Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].

Krivitzky A, Nguyen G, Gaudouen Y, Legrand M, Cohen R.

Drugs. 1998;56 Suppl 2:31-43. Review. French.

PMID:
9813740
6.

Arterial hypertension and ischaemic stroke.

Droste DW, Ritter MA, Dittrich R, Heidenreich S, Wichter T, Freund M, Ringelstein EB.

Acta Neurol Scand. 2003 Apr;107(4):241-51. Review.

PMID:
12675696
7.

Bevacizumab-induced hypertension: pathogenesis and management.

Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K.

BioDrugs. 2011 Jun 1;25(3):159-69. doi: 10.2165/11590180-000000000-00000. Review.

PMID:
21627340
8.

[Nephrotoxicity--proteinuria and hypertension--].

Ando M.

Gan To Kagaku Ryoho. 2008 Oct;35(10):1649-53. Japanese.

PMID:
18931564
9.

Management of hypertension in angiogenesis inhibitor-treated patients.

Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP.

Ann Oncol. 2009 May;20(5):807-15. doi: 10.1093/annonc/mdn713. Epub 2009 Jan 15. Review.

10.

Ambulatory blood pressure improves prediction of cardiovascular risk: implications for better antihypertensive management.

Krakoff LR.

Curr Atheroscler Rep. 2013 Apr;15(4):317. doi: 10.1007/s11883-013-0317-9. Review.

PMID:
23423525
11.

Pathogenesis of pulmonary arterial hypertension: lessons from cancer.

Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, Huertas A, Humbert M, Montani D.

Eur Respir Rev. 2013 Dec;22(130):543-51. doi: 10.1183/09059180.00007513. Review.

12.

ESH-ESC guidelines for the management of hypertension.

Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B.

Herz. 2006 Jun;31(4):331-8.

PMID:
16810473
13.

[A case of therapy for bevacizumab-induced hypertension].

Yasu T, Miyasaka Y, Chubachi H, Shimoyama R.

Gan To Kagaku Ryoho. 2009 Jan;36(1):143-5. Japanese.

PMID:
19151582
14.

Treatment of bevacizumab-induced hypertension by amlodipine.

Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S, Billemont B, Knebelmann B, Goldwasser F.

Invest New Drugs. 2012 Apr;30(2):702-7. doi: 10.1007/s10637-010-9549-5. Epub 2010 Sep 29.

PMID:
20878444
15.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee.

J Natl Cancer Inst. 2010 May 5;102(9):596-604. doi: 10.1093/jnci/djq091. Epub 2010 Mar 29.

16.

[Retrospective studies and prospects of therapy for hypertension].

Maisch B, Brilla C, Kruse T, Noll B, Bethge C.

Herz. 1995 Dec;20(6):370-89. Review. German.

PMID:
8582697
17.

Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.

Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM.

Can J Cardiol. 2014 May;30(5):534-43. doi: 10.1016/j.cjca.2014.02.011. Epub 2014 Feb 25. Review.

PMID:
24786444
18.

[Modern antihypertensive drug therapy].

Spieker C, Barenbrock M, Rahn KH.

Fortschr Med. 1996 Nov 20;114(32):425-30. Review. German.

PMID:
9064265
19.
20.

The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.

Thanigaimani S, Kichenadasse G, Mangoni AA.

Curr Vasc Pharmacol. 2011 May;9(3):358-80. Review.

PMID:
20807189
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk